Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans

Journal of Bacteriology

Volumn 183, Issue 10, 2001, Pages 2971-2978

  Cowen, Leah E ^a   Kohn, Linda M ^a   Anderson, James B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COMPETITIVE INHIBITION; EVOLUTION; FITNESS; GENETIC MARKER; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; EVOLUTION; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPHENOLIC ACID;

CANDIDA ALBICANS;

EID: 0035036088     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.183.10.2971-2978.2001     Document Type: Article

References (45)

1. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1):S43-S53.
2. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493.
3. Austin, D. J., K. G. Kristinsson, and R. M. Anderson. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl. Acad. Sci. USA 96:1152-1156.
4. Barbosa, T. M., and S. B. Levy. 2000. The impact of antibiotic use on resistance development and persistence. Drug Resist. Updates 3:303-311.
5. Beckerman, J., H. Chibana, J. Turner, and P. T. Magee. 2001. Single-copy IMH3 allele is sufficient to confer resistance to mycophenolic acid in Candida albicans and to mediate transformation of clinical Candida species. Infect. Immun. 69:108-114.
6. Björkman, J., and D. I. Andersson. 2000. The cost of antibiotic resistance from a bacterial perspective. Drug Resist. Updates 3:237-245.
7. Björkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson.. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
8. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type I to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
9. Bouma, J. E., and R. E. Lenski. 1988. Evolution of a bacteria/plasmid association. Nature 335:351-352.
10. Bull, J., and B. Levin. 2000. Mice are not furry petri dishes. Science 287: 1409-1410.
11. Cohan, F. M., E. C. King, and P. Zawadzki. 1994. Amelioration of the deleterious pleiotropic effects of an adaptive mutation in Bacillus subtilis. Evolution 48:81-95.
12. Cowen, L. E., D. Sanglard, D. Calabrese, C. Sirjusingh, J. B. Anderson, and L. M. Kohn. 2000. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182:1515-1522.
13. Crandall, K. A., C. R. Kelsey, H. Imamichi, H. C. Lane, and N. P. Salzman. 1999. Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Mol. Biol. Evol. 16:372-382.
14. De Backer, M. D., P. T. Magee, and J. Pla. 2000. Recent developments in molecular genetics of Candida albicans. Annu. Rev. Microbiol. 54:463-498.
15. Engels, A. J. G., and M. A. de Waard. 1996. Fitness of isolates of Erysiphe graminis f. sp. tritici with reduced sensitivity to fenpropimorph. Crop Protect. 15:771-777.
16. Georgopapadakou, N. H. 1998. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1:547-557.
17. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371-373.
18. Hsiang, T., L. Yang, and W. Barton. 1998. Relative virulence of isolates of Sclerotinia homoeocarpa with varying sensitivity to propiconazole. Eur. J. Plant Pathol. 104:163-169.
19. Korona, R. 1996. Genetic divergence and fitness convergence under uniform selection in experimental populations of bacteria. Genetics 143:637-644.
20. Lenski, R. E. 1997. The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found. Symp. 207:131-140.
21. Lenski, R. E., J. A. Mongold, P. D. Sniegowski, M. Travisano, F. Vasi, P. J. Gerrish, and T. M. Schmidt. 1998. Evolution of competitive fitness in experimental populations of E. coli: what makes one genotype a better competitor than another? Antonie Leeuwenhoek 73:35-47.
22. Lenski, R. E., M. R. Rose, S. C. Simpson, and S. C. Tadler. 1991. Long-term experimental evolution in Escherichia coli. I. Adaptation and divergence during 2,000 generations. Am. Nat. 138:1315-1341.
23. Lenski, R. E., and M. Travisano. 1994. Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. Proc. Natl. Acad. Sci. USA 91:6808-6814.
24. Levin, B. R., M. Lipsitch, V. Perrot, S. Schrag, R. Antia, L. Simonsen, N. M. Walker, and F. M. Stewart. 1997. The population genetics of antibiotic resistance. Clin. Infect. Dis. 24(Suppl. 1):S9-S16.
25. Levin, B. R., V. Perrot, and N. Walker. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997.
26. Levin, S. A., and V. Andreasen. 1999. Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings. Proc. Natl. Acad. Sci. USA 96:800-801.
27. Levy, S. B. 1994. Balancing the drug-resistance equation. Trends Microbiol. 2:341-342.
28. Marr, K. A., T. R. Rustad, J. H. Rex, and T. C. White. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. 43: 1383-1386.
29. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
30. Nijhuis, M., C. A. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-I evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
31. Nyhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
32. O'Brien, T. F. 1997. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin. Infect. Dis. 24(Suppl. 1):S2-S8.
33. Paquin, C. E., and J. Adams. 1983. Relative fitness can decrease in evolving asexual populations of S. cerevisiae. Nature 306:368-371.
34. Peever, T. L., and M. G. Milgroom. 1994. Lack of correlation between fitness and resistance to sterol biosynthesis-inhibiting fungicides in Pyrenophora teres. Phytopathology 84:515-519.
35. Raposo, R., V. Gomez, T. Urrutia, and P. Melgarejo. 2000. Fitness of Botrytis cinerea associated with dicarboximide resistance. Phytopathology 90:1246-1249.
36. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
37. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
38. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. R. Soc. Lond. B 264:1287-1291.
39. Travisano, M., and R. E. Lenski. 1996. Long-term experimental evolution in Escherichia coli. IV. Targets of selection and the specificity of adaptation. Genetics 143:15-26.
40. Travisano, M., J. A. Mongold, A. F. Bennett, and R. E. Lenski. 1995. Experimental tests of the roles of adaptation, chance, and history in evolution. Science 267:87-90.
41. Vasi, F., M. Travisano, and R. E. Lenski. 1994. Long-term experimental evolution in Escherichia coli. II. Charges in life-history traits during adaptation to a seasonal environment. Am. Nat. 144:432-456.
42. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
43. Wright, S. 1982. Character change, speciation, and the higher taxa. Evolution 36:427-443.
44. Wright, S. 1988. Surfaces of selective value revisited. Am. Nat. 131:115-123.
45. Xu, J., A. R. Ramos, R. Vilgalys, and T. G. Mitchell. 2000. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J. Clin. Microbiol. 38:1214-1220.